Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients Undergoing Caesarean Section

Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients With Stenotic Valvular Heart Disease Undergoing Caesarean Section

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05110482

Enrollment

Registered

2021-11-08

Start date

2021-11-30

Completion date

2023-06-30

Last updated

2023-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Effect of Oxytocic Drugs

Brief summary

Postpartum hemorrhage (PPH) is the primary cause of nearly one quarter of all maternal deaths globally. Management of uterine tone after delivery involves giving a prophylactic uterotonic and the use of controlled cord traction to facilitate delivery of the placenta and minimize blood loss. Syntocinon and carbetocin are the most commonly used drugs ,During caesarean delivery of stenotic valvular disease patient, the anesthesiologist have an important question: what is the best drug used for prevention of PPH with minimal hemodynamic effect regarding Systemic vascular resistance (SVR), Cardiac out put (COP),Heart rate ( HR), blood pressure? As uterotonic drugs may cause severe hypotension, decrease in SVR and COP that may not be tolerated by these patients .this thesis aims to compare between syntocinon and carbetocin regarding their effect on cardiac output and systemic vascular resistance using cardiometry in cardiac patients with stenotic lesions during caesarean delivery.

Interventions

DRUGSyntocinon

uterotonic drugs

DRUGCarbetocin

uterotonic drug

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Pregnant female single tone \>38 weeks * Age :18-45 years old. * patient with ASA III * Cardiac patients ( mild and moderate mitral stenosis-aortic stenosis valve disease )

Exclusion criteria

* Other cardiac conditions (valve regurge, cardiomyopathy, heart failure,severe mitral stenosis, severe aortic stenosis, severe pulmonary hypertension) * Pregnancy hypertensive disorders (eclampsia,preeclampsia) * Abnormal placental attachment (accrete,percreta,increta) * Patients with bleeding disorders * patient with high risk of postpartum haemorrhage

Design outcomes

Primary

Measure	Time frame	Description
Cardiac output	intraoperative	Average Cardiac output after study drug administration

Secondary

Measure	Time frame	Description
systemic vascular resistance	intraoperative	Systemic vascular resistance every 2 minute till end of surgery

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026